GT Biopharma IncNASDAQ:GTBP
- LAST PRICE0.7877
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.7900/ 2
- Ask / Lots0.8500/ 10
- Open / Previous Close0.8700 / 0.7877
- Day Range
- 52 Week Range
- Volume120,413
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GTBP |
|---|---|---|
| 09:32 ET | 150 | 0.87 |
| 09:33 ET | 234 | 0.869226 |
| 09:50 ET | 100 | 0.85 |
| 10:00 ET | 100 | 0.85 |
| 10:13 ET | 100 | 0.8495 |
| 11:02 ET | 100 | 0.8494 |
| 11:14 ET | 100 | 0.83 |
| 11:20 ET | 200 | 0.8397 |
| 11:21 ET | 700 | 0.8494 |
| 11:23 ET | 100 | 0.8493 |
| 11:30 ET | 307 | 0.8295 |
| 11:36 ET | 100 | 0.829 |
| 11:41 ET | 100 | 0.811 |
| 11:45 ET | 350 | 0.8494 |
| 11:50 ET | 100 | 0.81 |
| 11:56 ET | 100 | 0.81 |
| 12:08 ET | 300 | 0.84 |
| 12:15 ET | 100 | 0.81 |
| 12:26 ET | 300 | 0.825 |
| 12:28 ET | 100 | 0.81 |
| 12:30 ET | 100 | 0.84 |
| 12:44 ET | 8978 | 0.81 |
| 12:48 ET | 1300 | 0.8291 |
| 01:02 ET | 100 | 0.815492 |
| 01:04 ET | 744 | 0.8002 |
| 01:06 ET | 365 | 0.83 |
| 01:08 ET | 22249 | 0.73 |
| 01:09 ET | 3686 | 0.74 |
| 01:11 ET | 2560 | 0.75 |
| 01:13 ET | 387 | 0.7499 |
| 01:15 ET | 1200 | 0.748999 |
| 01:18 ET | 1600 | 0.7461 |
| 01:20 ET | 900 | 0.746 |
| 01:22 ET | 3420 | 0.7469 |
| 01:24 ET | 300 | 0.746 |
| 01:29 ET | 1100 | 0.7469 |
| 01:31 ET | 7212 | 0.7203 |
| 01:33 ET | 100 | 0.74 |
| 01:36 ET | 100 | 0.7202 |
| 01:38 ET | 2400 | 0.7202 |
| 01:40 ET | 3979 | 0.7253 |
| 01:42 ET | 100 | 0.74 |
| 01:44 ET | 400 | 0.727 |
| 01:45 ET | 400 | 0.7465 |
| 01:47 ET | 1262 | 0.7467 |
| 01:49 ET | 3820 | 0.7401 |
| 01:51 ET | 8200 | 0.7401 |
| 01:56 ET | 200 | 0.7459 |
| 01:58 ET | 860 | 0.7409 |
| 02:00 ET | 1173 | 0.740111 |
| 02:02 ET | 10100 | 0.7625 |
| 02:03 ET | 10200 | 0.7643 |
| 02:14 ET | 1000 | 0.7742 |
| 02:23 ET | 1300 | 0.7743 |
| 02:27 ET | 100 | 0.7785 |
| 02:32 ET | 100 | 0.7743 |
| 02:38 ET | 400 | 0.7743 |
| 02:48 ET | 300 | 0.78 |
| 02:52 ET | 550 | 0.7738 |
| 02:54 ET | 100 | 0.7741 |
| 02:57 ET | 924 | 0.7745 |
| 03:01 ET | 400 | 0.7745 |
| 03:03 ET | 100 | 0.7745 |
| 03:08 ET | 516 | 0.7745 |
| 03:12 ET | 100 | 0.78 |
| 03:19 ET | 100 | 0.78 |
| 03:21 ET | 100 | 0.7768 |
| 03:26 ET | 446 | 0.78 |
| 03:28 ET | 400 | 0.7751 |
| 03:35 ET | 100 | 0.7842 |
| 03:37 ET | 588 | 0.7801 |
| 03:39 ET | 100 | 0.7954 |
| 03:44 ET | 200 | 0.7954 |
| 03:48 ET | 200 | 0.7954 |
| 03:50 ET | 1000 | 0.7877 |
Jan 30, 2023
Beyond Air Affiliate Beyond Cancer Names Gavin Choy Chief Operating Officer, from 8:10AM ET on Monday Jan 30, 2023 by MT Newswires
8:10AM ET on Monday Jan 30, 2023 by MT Newswires
Jan 5, 2023
--EF Hutton Starts GT Biopharma at Hold With $2 Price Target, from 7:44AM ET on Thursday Jan 05, 2023 by MT Newswires
7:44AM ET on Thursday Jan 05, 2023 by MT Newswires
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
GT Biopharma Inc | 27.0M | -0.8x | --- |
Shuttle Pharmaceuticals Inc | 28.1M | 0.0x | --- |
Nunzia Pharmaceutical Corp | 26.1M | -0.3x | --- |
Sunshine Biopharma Inc | 26.2M | -13.6x | --- |
Protect Pharmaceutical Corp | 25.4M | -33.3x | --- |
Cadrenal Therapeutics Inc | 29.9M | 0.0x | --- |
Company Information
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The Company's TriKE platform generate therapeutics designed to harness and enhance the cancer killing abilities of a patient's own natural killer (NK) cells. GTB-3550 is the Company's TriKE product candidate, which is a single-chain, tri-specific recombinant fusion protein construct consisting of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. The Company is focused on studying this anti-CD16-IL-15-anti-CD33 TriKE in CD33 positive leukemias, a marker expressed on tumor cells in acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS).
Contact Information
- Headquarters
- 8000 MARINA BLVD, SUITE 100BRISBANE, CA, United States 94005
- Phone
- 310-551-4020
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board, Interim Chief Executive Officer
- Michael Breen
- Independent Vice Chairman of the Board
- Bruce Wendel
- Chief Financial Officer
- Manu Ohri
- Consulting Chief Scientific Officer
- Jeffrey Miller
- Chief Clinical Development Officer
- Gavin Choy
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $25.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 32.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.95 |
EPS | $-1.00 |
Book Value | $0.68 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
